Ten-Year Findings from a Randomized Comparison of Coronary Artery Disease Therapies

Compared with medical therapy, revascularization improved some long-term outcomes in patients with stable multivessel disease.

In the Brazilian single-center MASS II trial, 611 patients with multivessel coronary artery disease (CAD), stable angina, and preserved left ventricular function were randomized to medical therapy (MT), percutaneous coronary intervention (PCI), or coronary artery bypass grafting (CABG). At 5-year follow-up, mortality was similar in all three groups (JW Cardiol May 9 2007). The MASS II authors now report results at an average follow-up of 11.4 years. The primary endpoint was a composite of total mortality, Q-wave myocardial infarction (MI), and refractory angina requiring revascularization.

A primary endpoint occurred in significantly fewer CABG patients (33%) than PCI or MT patients (42% and 59%, respectively). Cardiac mortality was lower in…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI